XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP)

FairStock Score: 52/100 — MIXED

Key Financials

Strengths

• High return on equity of 34.1% demonstrating efficient capital deployment
• Attractive 8.3% dividend yield providing steady income returns

Concerns

• Trades significantly above Graham Number ($13) with negative 105% margin of safety—limited downside protection
• Revenue declining at 38.9% year-over-year signals potential demand weakness or market share loss

AI Analysis

XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock is a micro-cap healthcare company. The business generates $52 million in annual revenue with a 9.0% net margin. From a quality standpoint, XOMA shows strong 34% ROE and moderate 1.27x debt-to-equity. On valuation, the stock is trading at a premium 25.9x earnings, with trades far above its Graham Number ($13) with no margin of safety. Growth dynamics show revenue growing at -38.9% and profit growth of 253.8%. The 8.3% dividend yield adds an income component for patient holders. Our composite FairStock Score of 52/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer